Home
Sitemap
Contact Us
KOR
About PGRC
Research
Acivity
Product
Service
Board
×
About RGRC
Message
Introduction
History
Organization
Members
Research Facilities
Research
Clinical Pharmacology
Genomics
Proteomics
Metabolomics
Informatics
Activity
NRL
PRCDM
Product
Technology & Resources
Publications
Proceedings
Patents
Others
Service
Service
Board
Schedule
Notice
News
Photo
Related Site
Contact Us
KOR
Publications
Product
Technology & Resources
Publications
Proceedings
Patents
Others
Projects :
Select
BMRC
BMRC, Japan Fund
BMRC, PRCDM
BMRC, ü
cPMTb
FRONTIER
FRONTIER, PRCDM
NRL
NRL, PRCDM
PRCDM
PRCDM,
RCTC
RCTC, BMRC
Published Dates :
Select
2006-International
2006-Domestic
2005-International
2005-Domestic
2004-International
2004-Domestic
2003-International
2003-Domestic
2007-International
2007-Domestic
Select All
·
Anh NK, Phat NK, Yen NTH, Jayanti RP, Thu VTA, Park YJ, Cho YS, Shin JG, Kim DH, Oh JY, Long NP
Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring (cPMTb)
Biomed Pharmacother. 158:114187 / 2023.02 [
LINK
]
·
Jang YN, Cheong WY, Park GR, Kim YM, Ha JB, Ahn SZ
Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma (cPMTb)
J Pers Med. 13(2):188 / 2023.01 [
LINK
]
·
Anh NK, Tung PM, Kim MJ, Long NP, Cho YS, Kim DH, Shin JG
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS (cPMTb)
Molecules. 27(23):8607 / 2022.12 [
LINK
]
·
Le TK, Park YJ, Cha GS, Oktavia FARH, Kim DH, Yun CH
Roles of Human Liver Cytochrome P450 Enzymes in Tenatoprazole Metabolism (cPMTb)
Pharmaceutics. 15(1):23 / 2022.12 [
LINK
]
·
Ahn SZ
Building and analyzing machine learning-based warfarin dose prediction models using scikit-learn (cPMTb)
Transl Clin Pharmacol. 30(4):172-181 / 2022.12 [
LINK
]
·
Sidamo T, Rao PS, Aklillu E, Shibeshi W, Park YM, Cho YS, Shin JG, Heysell SK, Mpagama SG, Engidawork E
Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis (cPMTb)
Infect Drug Resist. 28:15:6839-6852 / 2022.11 [
LINK
]
·
Yen NTH, Park SM, Thu VTA, Phat NK, Cho YS, Yoon SJ, Shin JG, Kim DH, Oh JH, Long NP
Genome-wide gene expression analysis reveals molecular insights into the drug-induced toxicity of nephrotoxic agents (cPMTb)
Life Sci. 1:306:120801 / 2022.10 [
LINK
]
·
Howlader S, Kim MJ, Jony MR, Long NP, Cho YS, Kim DH, Shin JG
Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro (cPMTb)
Antimicrob Agents Chemother. 66(10):e0056522 / 2022.10 [
LINK
]
·
Alhawari H, Jarrar Y, Abulebdah D, Abaalkhail SJ, Alkhalili M, Alkhalili S, Alhawari H, Momani M, Obeidat MN, Fram RK, Salahat MA, Lee SJ
Effects of Vitamin D Receptor Genotype on Lipid Profiles and Retinopathy Risk in Type 2 Diabetes Patients: A Pilot Study (cPMTb)
J Pers Med. 12(9):1488 / 2022.09 [
LINK
]
·
Kim HK, Kim M, Marquez JC, Jeong SH, Ko TH, Noh YH, Kha PT, Choi HM, Kim DH, Kim JT, Yang YI, Ko KS, Rhee BD, Shubina LK, Makarieva TN, Yashunsky DY, Gerbst AG, Nifantiev NE, Stonik VA, Han J
Novel GSK-3 Inhibitor Neopetroside A Protects Against Murine Myocardial Ischemia/Reperfusion Injury (cPMTb)
JACC Basic Transl Sci. 7(11):1102-1116 / 2022.09 [
LINK
]
1
2
3
4
5
6
7
8
9
10
[Next]
title
name
subject